NASDAQ:SEEL Seelos Therapeutics (SEEL) Stock Price, News & Analysis $1.02 -0.08 (-7.27%) (As of 10/31/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Seelos Therapeutics Stock (NASDAQ:SEEL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Seelos Therapeutics alerts:Sign Up Key Stats Today's Range$1.01▼$1.1950-Day Range$0.99▼$5.4152-Week Range$0.82▼$729.60Volume7,703 shsAverage Volume182,975 shsMarket Capitalization$379,440.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewSeelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.Read More… Unveiled: NVIDIA’s "Secret Royalty" Program (Ad)Did you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?Click Here to learn how to get in now >>> Receive SEEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Seelos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SEEL Stock News HeadlinesSeelos Announces Second Postponement of its Annual Meeting of StockholdersOctober 24, 2024 | prnewswire.comSeelos Therapeutics Delisted From Nasdaq, Will Transition To OTC MarketOctober 16, 2024 | benzinga.comUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?October 31, 2024 | Behind the Markets (Ad)Seelos gets Nasdaq delisting noticeOctober 15, 2024 | msn.comSeelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter MarketOctober 15, 2024 | prnewswire.comSeelos Announces Postponement of its Annual Meeting of StockholdersSeptember 26, 2024 | prnewswire.comSeelos Therapeutics, Inc.: Seelos Therapeutics Announces 1-for-16 Reverse Stock SplitSeptember 25, 2024 | finanznachrichten.deSeelos Therapeutics to execute 1-for-16 reverse stock splitSeptember 25, 2024 | msn.comSee More Headlines SEEL Stock Analysis - Frequently Asked Questions How have SEEL shares performed this year? Seelos Therapeutics' stock was trading at $177.92 at the beginning of the year. Since then, SEEL shares have decreased by 99.4% and is now trading at $1.02. View the best growth stocks for 2024 here. How were Seelos Therapeutics' earnings last quarter? Seelos Therapeutics, Inc. (NASDAQ:SEEL) announced its earnings results on Wednesday, August, 14th. The company reported $1.92 earnings per share (EPS) for the quarter. The firm had revenue of $0.38 million for the quarter. When did Seelos Therapeutics' stock split? Seelos Therapeutics shares reverse split on Friday, September 27th 2024. The 1-16 reverse split was announced on Wednesday, September 25th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. Who are Seelos Therapeutics' major shareholders? Top institutional shareholders of Seelos Therapeutics include Modera Wealth Management LLC (0.50%). View institutional ownership trends. How do I buy shares of Seelos Therapeutics? Shares of SEEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Seelos Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Seelos Therapeutics investors own include Block (SQ), Digital Turbine (APPS), Palantir Technologies (PLTR), Okta (OKTA), CrowdStrike (CRWD), SoFi Technologies (SOFI) and ChargePoint (CHPT). Company Calendar Last Earnings8/14/2024Today10/31/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SEEL CUSIPN/A CIK1017491 Webwww.seelostherapeutics.com Phone(646) 293-2100Fax858-436-8155Employees20Year Founded2016Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,880,000.00 Net Margins203.13% Pretax Margin203.13% Return on EquityN/A Return on Assets-431.47% Debt Debt-to-Equity RatioN/A Current Ratio0.08 Quick Ratio0.08 Sales & Book Value Annual Sales$2.20 million Price / Sales0.19 Cash FlowN/A Price / Cash FlowN/A Book Value($437.92) per share Price / Book0.00Miscellaneous Outstanding Shares372,000Free Float368,000Market Cap$412,920.00 OptionableOptionable Beta1.85 Social Links These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report This page (NASDAQ:SEEL) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seelos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seelos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
